Transplantation and Tumor Immunology
Why does a transplanted kidney from a stranger get destroyed within days? Why does a graft from an identical twin survive for decades? Why does an immune system exquisitely capable of clearing viruses so often fail to eliminate a tumor built from the patient's own cells? These two questions turn out to share a single mechanistic core. That core is the T cell's ability to distinguish self from non-self. It also involves the ways that distinction can be exploited, subverted, or overridden. Transplantation immunology is not really about surgery. It is about the discovery that peptide-loaded MHC molecules are essentially unique fingerprints of an individual. It also concerns the fact that T cells are shockingly promiscuous in recognizing foreign versions of them. Tumor immunology is the mirror problem. Cancer cells arise from self and carry mostly self-antigens. They also evolve under active immune pressure. So the very selective process meant to protect the host can end up sculpting a tumor that is invisible to it. Both fields sit at the intersection of basic T-cell biology (see T-Cell Activation) and the same tolerance mechanisms. When those mechanisms fail, they cause Autoimmunity. The big picture is that alloreactivity — the immune response against genetically different tissue — is not a rare pathological quirk. It is instead a predictable, almost mathematical consequence of how T-cell receptors are selected during development. And tumor immune evasion is not a passive failure. It is an active evolutionary process, immune editing, in which the immune system and the cancer co-evolve. Understanding both has practically remade modern medicine. Organ transplantation, bone marrow transplantation, and checkpoint-inhibitor cancer immunotherapy all rest on the mechanisms described here. This article works through the molecular basis of graft rejection (direct and indirect allorecognition, hyperacute/acute/chronic rejection, GVHD). It covers the classical experiments that established histocompatibility genetics and immune surveillance. It also includes worked quantitative examples (a family HLA-matching problem and a tumor-editing timeline). Finally, it addresses the clinical and biotechnological payoff — immunosuppression, matching algorithms, and checkpoint blockade.
- Graft rejection is driven by T cells recognizing foreign MHC molecules either directly (intact allo-MHC) or indirectly (allo-peptides presented by self-MHC).
- Because up to 1–10% of all T cells can react to any given foreign MHC, alloreactivity is far stronger than antipathogen responses — this is why transplants need lifelong immunosuppression.
- Rejection has three temporal patterns — hyperacute (antibody, minutes–hours), acute (T-cell, days–weeks), chronic (mixed, months–years) — each with a distinct mechanism.
- Tumors express antigens (neoantigens, overexpressed self, oncofetal, viral) that CD8+ T cells can recognize; immune surveillance was proven using immunodeficient mice with elevated spontaneous and carcinogen-induced tumor rates.
- Cancer immunoediting has three phases — elimination, equilibrium, escape — a Darwinian process in which the immune system selects for poorly antigenic, immunosuppressive tumor variants.
- Checkpoint inhibitors (anti-CTLA-4, anti-PD-1/PD-L1) work by releasing brakes on T cells rather than adding new specificity, turning basic transplantation/tumor immunology directly into a Nobel-winning therapy.
Graft rejection and tumor immune evasion are two faces of the same coin — the T-cell receptor's capacity to discriminate self from non-self peptide–MHC complexes, which protects against foreign tissue but must be circumvented or restored for transplants and tumors, respectively, to be tolerated or destroyed.
The core idea
The major histocompatibility complex (MHC) — called HLA (human leukocyte antigen) in humans — is the most polymorphic gene cluster in the vertebrate genome. Each person inherits one HLA haplotype from each parent, and there are thousands of alleles at each of the classical loci (HLA-A, -B, -C for class I; HLA-DR, -DQ, -DP for class II). Because T-cell receptors (TCRs) are selected during thymic development to recognize self-peptide bound to self-MHC, any MHC molecule from another individual — loaded with a different repertoire of self-peptides and folded with a different surface topology — looks like a novel antigen to a large fraction of the T-cell repertoire. This is alloreactivity: T cells reacting against allogeneic (genetically different, same-species) MHC. Tumor immunology asks the inverse question. A cancer cell is derived from the host's own tissue, so most of its proteins are self and should be tolerated. But cancer cells accumulate somatic mutations, re-express silenced developmental genes, and sometimes carry viral proteins (in virus-associated cancers). Peptides derived from these altered or abnormal proteins, presented on MHC class I, can be recognized by CD8+ cytotoxic T lymphocytes (CTLs) as tumor antigens. The immune system's capacity to detect and eliminate nascent tumors before they become clinically apparent is called immune surveillance; the process by which surviving tumors are shaped by immune pressure into less immunogenic, more evasive forms is cancer immunoediting. Both fields hinge on the same two-signal logic of T-cell activation (TCR engagement plus costimulation, or its absence leading to anergy), the same effector mechanisms (CTL-mediated killing via perforin/granzyme and Fas–FasL, and antibody-mediated complement/ADCC), and the same regulatory circuitry (Treg suppression, checkpoint molecules like CTLA-4 and PD-1) that governs tolerance and Autoimmunity more broadly.
Mechanism
1. Direct vs. indirect allorecognition. In direct allorecognition, a recipient T cell's TCR binds intact donor MHC molecules displayed on donor antigen-presenting cells (APCs, mainly dendritic cells) that migrate out of the graft into recipient lymph nodes. Because donor MHC molecules are structurally similar enough to self-MHC to engage the TCR, but different enough in the peptide-binding groove and bound peptide to be seen as foreign, a surprisingly large fraction of a recipient's naive T-cell repertoire — estimates range from roughly 1% to 10% of all T cells, compared with typically <0.001–0.01% for a given pathogen epitope — can respond. This "high-frequency alloreactivity" is why acute rejection is so fast and vigorous, and it reflects cross-reactivity: TCRs selected on self-MHC/self-peptide happen to also bind foreign-MHC/foreign-peptide combinations because TCR contact residues tolerate considerable structural degeneracy. In indirect allorecognition, recipient APCs endocytose shed donor MHC proteins (and other donor proteins), process them into peptides, and present donor-derived peptides on the recipient's own class II MHC to recipient CD4+ T cells — exactly like presentation of any foreign protein antigen. Indirect recognition is slower to develop but dominant in chronic rejection, because it persists as long as the graft continually sheds antigen, and it also draws in antibody responses since indirect-pathway CD4+ T cells provide help to B cells making anti-donor antibodies.
2. Effector mechanisms of rejection. Once alloreactive CD4+ and CD8+ T cells are activated in recipient lymph nodes (an T-Cell Activation event that includes proliferation and differentiation into effector cells), they traffic to the graft. CD8+ CTLs kill graft cells expressing donor class I MHC via perforin/granzyme-induced apoptosis and Fas-FasL signaling. CD4+ T cells secrete IFN-γ and other cytokines, activate macrophages, and provide help for antibody responses; macrophage-driven delayed-type hypersensitivity-like inflammation contributes substantially to tissue damage. Pre-existing or newly formed antibodies against donor blood-group antigens or HLA molecules can fix complement and trigger endothelial damage.
3. Three time-courses of rejection, each with a distinct mechanism.
| Type | Onset | Mechanism |
|---|---|---|
| Hyperacute | Minutes–hours | Pre-existing recipient antibodies (e.g., anti-ABO or anti-HLA from prior transfusion/pregnancy/transplant) bind graft endothelium, fix complement, cause thrombosis and infarction |
| Acute | Days–weeks | Primary T-cell response (direct + indirect allorecognition), cell-mediated cytotoxicity and cytokine-driven inflammation; the classical target of immunosuppressive drugs |
| Chronic | Months–years | Indirect allorecognition sustains low-grade T-cell/antibody responses; vascular smooth-muscle proliferation (graft arteriosclerosis) and fibrosis progressively occlude graft vasculature |
4. Graft-versus-host disease (GVHD) is the mirror-image problem seen in bone-marrow/hematopoietic stem cell transplantation: donor T cells transferred along with the graft recognize the recipient's tissues as foreign and attack the host's skin, gut, and liver. Because the donor immune system is naive to host antigens and numerically substantial, GVHD can be as dangerous as rejection itself; T-cell depletion of the graft reduces GVHD but also removes a beneficial "graft-versus-leukemia" effect in which donor T cells kill residual host leukemic cells.
5. Tumor antigen categories. Tumor antigens recognized by T cells fall into several classes:
- Tumor-specific neoantigens — peptides from mutated proteins unique to the cancer cell, generated by somatic point mutations, indels, or gene fusions; these are the most immunogenic because they are truly foreign to the thymically-educated repertoire.
- Tumor-associated antigens (overexpressed self) — normal proteins overexpressed in tumors (e.g., HER2 in some breast cancers) that may break tolerance quantitatively.
- Cancer-testis antigens — proteins normally restricted to immune-privileged testis/placenta, aberrantly re-expressed in tumors (e.g., MAGE family), appearing "foreign" to a peripheral immune system that has not been tolerized to them outside the privileged site.
- Oncofetal antigens — proteins normally expressed only during fetal development (e.g., alpha-fetoprotein, CEA), useful clinically as tumor markers.
- Viral antigens — in virus-associated cancers (HPV E6/E7 in cervical cancer, EBV antigens in some lymphomas), genuinely foreign viral proteins are the antigen.
6. Immune surveillance and immunoediting. The surveillance hypothesis (Burnet and Thomas, 1957 onward) proposed that the immune system continuously detects and destroys nascent malignant cells, and that clinical cancer represents a failure of this process. Modern immunoediting theory elaborates this into three phases:
- Elimination — innate immunity (NK cells sensing stress ligands and reduced MHC-I; macrophages) plus adaptive CTLs detect and destroy transformed cells, aided by inflammatory signals (type I interferons, danger-associated molecular patterns) from the growing tumor.
- Equilibrium — surviving tumor cell variants are held in a dynamic standoff with adaptive immunity; T cells continually kill immunogenic clones, exerting selective (Darwinian) pressure, without eliminating the tumor entirely. This phase can last years and is the immunological basis of tumor dormancy.
- Escape — tumor variants that have lost antigenicity (downregulated MHC-I, lost the mutated antigen) or gained immunosuppressive capacity (expressing PD-L1, recruiting regulatory T cells and myeloid-derived suppressor cells, secreting TGF-β/IL-10) outgrow, becoming clinically apparent cancer.
Escape mechanisms mirror rejection biology in reverse: rather than exploiting the T cell's alloreactive vigor, tumors exploit the T cell's normal off-switches — PD-1/PD-L1 and CTLA-4 checkpoint pathways, which physiologically limit collateral damage during infections, become co-opted to blunt anti-tumor immunity.
The evidence
Peter Medawar and the discovery of acquired immunological tolerance and adaptive rejection (1940s–1950s). During WWII, Medawar studied skin grafts in burn patients and noticed second-set grafts from the same donor were rejected faster than first grafts — implying immunological memory, not merely tissue incompatibility. Working with rabbits and later mice, Medawar showed that skin graft rejection was mediated by lymphocytes (demonstrable by adoptive transfer of lymphocytes from a sensitized animal, which caused accelerated "second-set" rejection in a naive host) rather than by antibodies alone, and that rejection was donor-specific. Building on Ray Owen's 1945 observation that dizygotic cattle twins sharing a placental blood supply become stable chimeras tolerant of each other's blood cells, Medawar, Rupert Billingham, and Leslie Brent showed in 1953 that injecting neonatal mice with allogeneic cells from a future donor strain induced acquired immunological tolerance: as adults, those mice accepted skin grafts from that donor strain but rejected third-party grafts. This proved tolerance is actively learned during development, not a fixed property of the antigen, and it directly foreshadowed T-Cell Activation models of central tolerance. Medawar shared the 1960 Nobel Prize with Macfarlane Burnet, whose clonal selection theory explained the cellular basis of what Medawar had observed.
George Snell and the genetics of histocompatibility. Using classical Mendelian breeding of congenic mouse strains (differing at a single genetic locus by repeated backcrossing), Snell in the 1940s–1950s mapped rejection to a single, highly polymorphic genetic region he named H-2 (histocompatibility-2) in mice — the murine MHC. He showed rejection segregated with specific alleles at this locus in Mendelian ratios, establishing that transplant rejection is a genetically deterministic immune response, not a nonspecific tissue reaction. Snell, Jean Dausset (who identified the first human leukocyte antigen, HLA, in patients who had received multiple transfusions and developed antibodies against donor leukocytes), and Baruj Benacerraf (who linked immune responsiveness genes to the MHC) shared the 1980 Nobel Prize for establishing the genetic basis of histocompatibility.
Zinkernagel and Doherty: MHC restriction (1974). Using lymphocytic choriomeningitis virus (LCMV)–infected mice, Rolf Zinkernagel and Peter Doherty found that CTLs from an infected mouse of strain A could kill LCMV-infected target cells from strain A, but not LCMV-infected target cells from strain B — even though both were infected with the identical virus. CTLs required the target cell to share MHC haplotype with the CTL donor. This "MHC restriction" experiment revealed that T cells recognize antigen only in the context of self-MHC, the mechanistic bedrock explaining both indirect allorecognition (foreign peptide on self-MHC) and direct allorecognition (recognition of foreign MHC itself, understood as cross-reactivity of a self-MHC-restricted receptor repertoire). They won the 1996 Nobel Prize.
The immune surveillance hypothesis, tested and revived. Burnet and Lewis Thomas proposed cancer immune surveillance in 1957, but early tests using then-available nude (athymic) mice gave ambiguous results — nude mice did not show dramatically increased spontaneous tumors, which for decades was taken as evidence against surveillance. The hypothesis was rehabilitated when better immunodeficient models became available. In a pivotal 2001 study, Robert Schreiber's group compared mice lacking a functional IFN-γ response and/or RAG2 (and hence lacking T, B, and NKT cells) to wild-type mice. RAG2⁻/⁻ mice, and mice deficient in IFN-γ signaling, developed spontaneous epithelial tumors more frequently and showed markedly greater susceptibility to chemical (methylcholanthrene, MCA) carcinogen-induced sarcomas than immunocompetent controls. Crucially, tumors that arose in immunodeficient mice were often more immunogenic than tumors arising in immunocompetent mice: when transplanted into wild-type recipients, a significant fraction of immunodeficient-mouse tumors were rejected, whereas tumors that had arisen (and survived immune pressure) in immunocompetent mice were accepted — direct evidence that an intact immune system had "edited" surviving tumors to be less antigenic. This experiment (Shankaran et al., Nature, 2001) is the modern proof of both immune surveillance and immunoediting, replacing decades of ambiguity with a controlled, quantitative demonstration.
Clinical corroboration. Organ transplant recipients on long-term immunosuppression show substantially elevated rates of certain cancers (e.g., skin cancers, virus-associated lymphomas), and immunosuppressed HIV/AIDS patients show elevated rates of Kaposi sarcoma and lymphoma — consistent with surveillance operating continuously in immunocompetent people. The clinical success of immune checkpoint inhibitors (dramatic, durable tumor regressions in melanoma and other cancers upon anti-CTLA-4 or anti-PD-1 treatment) is itself strong evidence that endogenous, tumor-reactive T cells exist in patients but are actively suppressed — exactly as the equilibrium/escape model predicts.
Worked examples
Example 1 — HLA matching in a family for kidney transplant. HLA genes are inherited as linked haplotypes (one from each parent), so full siblings have a predictable probability of matching. Suppose the parents' haplotypes are:
- Father: haplotype A / haplotype B
- Mother: haplotype C / haplotype D
Each child independently inherits one paternal haplotype (A or B, 50/50) and one maternal haplotype (C or D, 50/50), giving four equally likely combinations: AC, AD, BC, BD (each probability 1/4). A patient (say, child 1 = AC) needs a kidney and has three siblings. What is the probability a given sibling is a full (two-haplotype) match? Only a sibling who also inherited AC matches both haplotypes exactly — probability 1/4 per sibling. With 3 siblings, the probability that at least one is a full match is: P(at least one match) = 1 − P(no sibling matches) = 1 − (3/4)³ = 1 − 0.422 = 0.578, i.e., about 58%. If instead we ask for a "half-match" (haploidentical) sibling — sharing exactly one haplotype — the per-sibling probability is 1/2 (either AD or BC gives one shared haplotype with AC), which is why haploidentical living-related transplants are far more often feasible than full matches, though they carry a higher rejection/GVHD risk requiring more intensive immunosuppression. This calculation is exactly why transplant centers screen full sibling sets first and why unrelated-donor registries (which must match across an effectively astronomical number of HLA allele combinations) require millions of registered donors to find sufficiently close matches for patients without a related match.
Example 2 — Reading a tumor's evolutionary trajectory through immunoediting. A patient's melanoma is biopsied at diagnosis and again after relapse following initial response to anti-PD-1 checkpoint therapy. Whole-exome sequencing shows:
- Diagnosis tumor: expresses a strongly immunogenic neoantigen (from a driver mutation), normal HLA class I expression, low PD-L1.
- Relapse tumor: neoantigen-encoding mutation is still present, but the specific HLA allele needed to present that neoantigen (HLA-B*compared at diagnosis) is lost via loss-of-heterozygosity in the relapse clone; PD-L1 expression is markedly elevated.
How do you interpret this using immunoediting logic? At diagnosis, the tumor sits in equilibrium/early escape: T cells specific for the neoantigen are present (that's plausibly why checkpoint blockade produced an initial response, by releasing PD-1-mediated suppression of those T cells). Under sustained immune pressure from checkpoint-unleashed T cells, the tumor cell population is subjected to strong selection: any subclone that has lost the presenting HLA allele can no longer display the neoantigen and becomes invisible to that T-cell clone, regardless of PD-1 blockade — an escape mechanism operating upstream of the checkpoint, at the level of antigen presentation itself. That HLA-loss subclone expands to dominate the relapse tumor. Elevated PD-L1 additionally reflects an active, largely futile local immune attack (a compensatory response to persistent IFN-γ from tumor-infiltrating T cells) rather than a stable evasion mechanism, since checkpoint blockade is already present. This is a textbook case of acquired resistance to immunotherapy through immunoediting: the very treatment applies the selective pressure that reveals — and can accelerate the emergence of — the antigen-loss escape variant. Clinically, this argues for combination approaches (e.g., pairing checkpoint blockade with therapies that don't depend solely on classical antigen presentation, such as NK-cell-engaging approaches, since NK cells preferentially kill MHC-I-low cells via "missing-self" recognition).
Common misconceptions & traps
| Misconception | Correction |
|---|---|
| "Blood type (ABO) matching is the main barrier to transplantation." | ABO matching prevents hyperacute rejection, but HLA (MHC) matching and ongoing T-cell alloreactivity are the dominant long-term barriers requiring lifelong immunosuppression. |
| "A perfectly HLA-matched graft needs no immunosuppression." | Even HLA-identical sibling grafts (except identical twins) differ at numerous "minor histocompatibility antigens" (polymorphic peptides from other genes presented on matched MHC), so some immunosuppression is still typically needed. |
| "Cancer cells are invisible to the immune system because they are 'self'." | Many tumors express genuinely foreign-looking neoantigens and are actively recognized; the problem is usually active suppression/evasion (checkpoint upregulation, MHC loss, Treg recruitment), not inherent invisibility. |
| "Immune surveillance failing means cancer 'escaped' once and for all in a single step." | Immunoediting is a continuous, multi-round Darwinian process (elimination → equilibrium → escape); equilibrium can last years, and immune pressure continues shaping the tumor even after clinical detection. |
| "Rejection is caused only by T cells; antibodies are irrelevant." | Antibody-mediated rejection (hyperacute and a major component of chronic rejection) is clinically critical and mechanistically distinct, involving complement fixation on graft endothelium rather than direct T-cell cytotoxicity. |
| "Checkpoint inhibitors add new anti-tumor immunity." | They do not create new specificities; they release pre-existing, endogenously generated tumor-reactive T-cell clones from inhibitory signaling, which is why patients lacking any tumor-reactive T cells to begin with often do not respond. |
The scientist behind it
Peter Brian Medawar trained as a zoologist at Oxford before turning, during the Second World War, to the urgent clinical problem of skin grafting for burn victims — work initiated at the request of the Medical Research Council studying why skin grafts from unrelated donors failed. His careful, quantitative comparisons of first-set versus second-set graft rejection in rabbits established that rejection was immunological and specific. Collaborating with Rupert Billingham and Leslie Brent at University College London and later the National Institute for Medical Research, Medawar performed the neonatal tolerance-induction experiments (inspired directly by Ray Owen's cattle-twin observations and by a theoretical prediction from Macfarlane Burnet) that proved tolerance could be actively induced by exposing an immature immune system to foreign antigen — the founding experiment of transplantation immunology and a direct forerunner of modern understanding of central and peripheral T-cell tolerance.
Origins · 1 minPeter Brian Medawar and how this was discovered
Medawar's neonatal tolerance experiments (with Billingham and Brent, 1953) demonstrated that immunological tolerance to foreign tissue could be actively acquired during development rather than being a fixed property of self-recognition — the conceptual foundation for both transplantation immunology and modern immune tolerance theory. He shared the 1960 Nobel Prize in Physiology or Medicine with Macfarlane Burnet.
Where this matters today
Solid organ and hematopoietic stem cell transplantation are now routine because of this mechanistic understanding: HLA typing and crossmatching predict and prevent hyperacute rejection; calcineurin inhibitors (cyclosporine, tacrolimus), antiproliferative agents (mycophenolate), and biologics (anti-CD25, anti-thymocyte globulin) target the T-cell activation steps described here to blunt acute rejection; and induction of donor-specific tolerance (using mixed chimerism protocols inspired directly by Medawar's neonatal tolerance experiments) is now achieved in some living-donor kidney transplant trials, allowing drug-free graft acceptance in select patients. Paired-donor kidney exchange programs and national marrow donor registries are direct engineering solutions to the HLA-matching probability problem worked through above. In oncology, understanding tumor antigens and immune evasion produced checkpoint inhibitor immunotherapy (anti-CTLA-4 ipilimumab; anti-PD-1/PD-L1 pembrolizumab, nivolumab, atezolizumab), which has transformed outcomes in melanoma, non-small-cell lung cancer, and other malignancies by releasing the brakes on endogenous tumor-reactive T cells — recognized by the 2018 Nobel Prize to James Allison and Tasuku Honjo. Chimeric antigen receptor (CAR) T-cell therapy engineers a patient's own T cells to recognize a chosen tumor surface antigen independent of MHC presentation, directly sidestepping the MHC-loss escape mechanism. Cancer vaccines targeting neoantigens exploit the same logic used to explain immunogenic tumor rejection in immunoediting studies. Meanwhile, monitoring for post-transplant malignancy in immunosuppressed patients, and balancing GVHD against graft-versus-leukemia effect in bone marrow transplantation, both directly apply the mechanistic trade-offs described here. As tumors and pathogens both exploit immune evasion strategies — MHC downregulation, immunosuppressive cytokines, decoy antigens — this body of transplantation and tumor immunology sets up the parallel logic used to understand Host-Pathogen Interactions, where analogous evasion tactics are deployed by viruses and intracellular bacteria.
Ask the tutor: How would you design an experiment to determine whether a patient's tumor relapse after checkpoint therapy is due to antigen loss versus T-cell exhaustion?
Why do identical twins not reject each other's transplanted organs?
Identical (monozygotic) twins are genetically identical, so every MHC/HLA allele and every minor histocompatibility antigen matches exactly between donor and recipient. Since T-cell alloreactivity depends on recognizing foreign MHC molecules (directly) or foreign peptides on self-MHC (indirectly), there is no allogeneic difference for either pathway to detect. A kidney transplanted between identical twins can therefore succeed with no immunosuppression at all — historically, the first successful long-term human kidney transplant (Joseph Murray, 1954) was performed between identical twins for exactly this reason, avoiding rejection entirely rather than treating it.
What is the difference between tumor-specific and tumor-associated antigens, and why does it matter clinically?
Tumor-specific antigens (mainly neoantigens from somatic mutations) exist only on cancer cells and never on normal tissue, so targeting them should, in principle, spare healthy cells. Tumor-associated antigens are normal self-proteins that are simply overexpressed or aberrantly expressed in cancer (like HER2 or cancer-testis antigens), meaning some normal cells may also express them at low levels. This matters because immunotherapies or CAR-T cells targeting tumor-associated antigens risk "on-target, off-tumor" toxicity against normal tissue, whereas targeting genuine neoantigens (now feasible with personalized neoantigen vaccines) offers greater tumor specificity, though neoantigens are unique to each patient and tumor, making them harder to target with off-the-shelf therapies.
Why does GVHD occur even when the recipient is well matched to the donor?
Graft-versus-host disease arises because the transplanted material (bone marrow or hematopoietic stem cells) contains mature donor T cells that see the recipient's tissues as foreign. Even in HLA-matched transplants, minor histocompatibility antigens — polymorphic peptides derived from genes elsewhere in the genome, presented on the shared (matched) MHC — differ between donor and recipient and can trigger indirect-style recognition by donor T cells. Because the donor T-cell repertoire has never been tolerized to these recipient-specific minor antigens, and because the recipient's tissues (skin, gut, liver) are extensively targeted, GVHD can be severe even in the "best case" matching scenario, which is why T-cell depletion or prophylactic immunosuppression is routinely used.
How can cancer cells escape immune detection by altering antigen presentation?
The classical route is downregulating or losing components of the antigen-processing machinery: reduced MHC class I expression, loss of beta-2-microglobulin (needed to stabilize MHC-I), or reduced TAP transporter/proteasome subunit expression, all of which reduce peptide loading and surface display of tumor antigens to CD8+ T cells. Alternatively, tumors can undergo loss-of-heterozygosity at the specific HLA allele needed to present a particular neoantigen, silencing recognition by one T-cell clone while retaining other MHC alleles. Cells with very low MHC-I can still be vulnerable to NK cells via "missing-self" recognition, so complete antigen-presentation shutdown is not cost-free for the tumor, which is one reason equilibrium can persist rather than tipping immediately to escape.
Is immune surveillance the same thing as immunoediting?
No — surveillance is the narrower claim that the immune system detects and eliminates nascent tumors, essentially the "elimination" phase alone. Immunoediting is the broader, more modern framework encompassing elimination, equilibrium, and escape, recognizing that immune interaction with a tumor doesn't stop at successful elimination or complete failure; it also actively reshapes (edits) the antigenic and immunogenic properties of any tumor cells that survive. Immunoediting explains why clinically detected cancers are often poorly immunogenic — not because tumors start out invisible, but because visible, immunogenic variants were eliminated earlier, leaving less visible variants to grow out.
Why does chronic rejection remain a problem even with modern immunosuppressive drugs that control acute rejection well?
Modern immunosuppressants (calcineurin inhibitors, antiproliferatives, biologics) largely target the acute, direct-allorecognition-driven T-cell response, and have made acute rejection far more manageable than a few decades ago. Chronic rejection, however, is driven predominantly by the indirect pathway — a slow, continuous trickle of donor antigen shed from the graft and presented by recipient MHC — which persists at low level despite standard immunosuppression and gradually drives vascular smooth muscle proliferation, intimal thickening (graft arteriosclerosis), and fibrosis. Because this process unfolds over months to years through cumulative, low-grade immune injury rather than a single acute burst, it is much harder to suppress with drugs timed and dosed for acute-phase immunity, and remains the leading cause of late graft loss.
What is the practical link between transplantation immunology and cancer immunotherapy?
Both fields depend on the identical T-cell machinery: TCR recognition of peptide-MHC, costimulation-dependent activation, and checkpoint-mediated restraint. Transplant immunology studies how to dial this system down (prevent unwanted rejection of healthy foreign tissue), while tumor immunology studies how to dial it back up (restore rejection of unhealthy self-derived tissue). The same molecules discovered through rejection research — CTLA-4 as a natural brake on alloreactive T cells, PD-1/PD-L1 as tolerance mechanisms limiting collateral damage during immune responses — turned out to be the exact molecules tumors hijack for immune evasion, which is why anti-CTLA-4 and anti-PD-1 antibodies, conceptually "anti-tolerance" drugs, became the foundation of modern checkpoint-inhibitor cancer therapy.